Home Tags Mylan
Congress will grill 7 top pharma executives over the high cost of drugs today. Here’s how they’re set to shift the blame.
Pharma CEOs are likely to blame drug rebates for the high cost of their treatments, echoing an argument the industry has been using frequently.
EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes
Consumer complaints about EpiPens were increasing, but its manufacturer wasn’t properly looking into those complaints, FDA inspectors warned in 2014.
A huge lawsuit accuses nearly 20 big drug companies, a billionaire, and 2 brothers-in-law of cozying up to hike drug prices. Here’s the inside s...
Business Insider is the first to report on the unredacted suit, which alleges frequent, close communications among employees of rival companies about how to increase prices.
Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky
The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.
The strange history of the EpiPen, the device developed by the military that turned into a billion-dollar business and now faces generic competition b...
Here's the story of how a common, lifesaving device became a controversial drug-pricing story, facing recalls, shortages, and now generic competition between Mylan and Teva.
Mylan stock dropped over 7% after it released its second quarter earning report. The company then announced that it was to undergo a strategic review.
The FDA on Wednesdsay said that there's a shortage of EpiPens in the US. Mylan, the company that distributes the emergency allergy medication, said that there are "intermittent supply constraints," but supply is available.
BI PRIME: Morgan Stanley compiled a list of large and liquid companies it thinks will get at least one tender offer over the next 12 months.
A lawsuit over price fixing by drugmakers is being massively expanded and shares of Mylan are plunging
The states are zeroing in on a man named Rajiv Malik, Mylan's president and executive director, along with Satish Mehta, CEO at Emcure Pharmaceuticals.
The FDA just approved a ‘complex generic drug’ and it’s sending one stock soaring and another crashing
The FDA on Tuesday approved a generic version of Copaxone, a drug that treats multiple sclerosis that generates about $3 billion in sales.